Nuclear Medicine Products
Come See Us
September 29, 2017
Our original Bedford MA Manufacturing facility has closed.
With all Pharmalucence products either fully transferred or in process for transfer to our Billerica MA facility, we have closed our original facility in Bedford MA.
February 14, 2017
New Second Lyophilzer Installation Project Begins
Pharmalucence is installing a second 180 sq. ft. IMA lyophilizer, which will double our capacity at our Billerica MA facility.
April 25, 2016
Pharmalucence receives FDA approval to commence manufacturing operations at its Billerica MA facility
The Pharmalucence manufacturing site located at 29 Dunham Rd., Billerica, MA has received FDA approval for drug product aseptic fill-finish manufacturing operations. Our Tc 99m Sulfur Colloid Kit will be the first product manufactured at this new facility. Pharmalucence is now in the process of transferring the manufacturing process for all of its other injectable products to this site.
March 24, 2015
2015 ISPE Facility of the Year Award Winners
Pharmalucence receives Honorable Mention for their new parenteral facility from the International Society for Pharmaceutical Engineering (ISPE).
July 18, 2014
Pharmalucence acquired by Sun Pharma July 15, 2014
Please see the attached announcement for details.
May 13, 2014
Pharmalucence announces divestiture of IBL 437C Blood Irradiator Service
MikRon Inc. to assume IBL 437C service business effective August 6, 2014. To contact MikRon for IBL 437C service, please contact them at (508) 589-4600 or email Jim Thomson at Jim@mikroninc.com.
April 30, 2014
Pharmalucence Aseptic Fill and Finish Facility Milestone - DMF Submission
Pharmalucence submits its DMF (Drug Master File) to FDA on Tuesday April 29, 2014.
December 09, 2013
Pharmalucence announces manufacturing contract at its new parenteral manufacturing facility in Billerica, MA
Pharmalucence, Inc. announced that it has entered into an agreement with Lantheus Medical Imaging, Inc. to serve as a contract manufacturer of DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension for contrast-enhanced echocardiography.
December 17, 2012
Pharmalucence to co-sponsor Aseptic Drug Manufacturing Symposium March 11-13, 2013
In partnership with Bosch, Pharmalucence is inviting Drug Manufacturing professionals from across the U.S. to attend "Innovation Symposium 2013, Injectable Drug Manufacturing" at the Marriott Hotel in Burlington MA.
November 20, 2012
Pharmalucence recognized with award from MassEcon.
Pharmalucence has been named as a "Rising Star" award winner for the Team Massachusetts Economic Impact Awards, awarded annually by MassEcon (Massachusetts Alliance for Economic Development).
Page 1 of 3
September 17, 2012
FDA grants Orphan Drug designation status to Sulfur Colloid.
Pharmalucence receives FDA notification that Sulfur Colloid Injection (SCI) has been granted Orphan Drug designation status and seven years of market exclusivity for its use in lymph node localization in melanoma patients.
August 27, 2012
Pharmalucence has been selected as one of 19 finalists for the 9th annual MASSECON 2012.
August 16, 2012
Pharmalucence receives FDA approval for use of Sulfur Colloid Injection (SCI) to locate lymph nodes in malignant melanoma patients.
May 03, 2012
“Making it in Massachusetts: A Small Company’s Road to the CMO Market” at Interphex 2012.
Glenn Alto, President and CEO, and Ed Connolly, COO, to present “Making it in Massachusetts: A Small Company’s Road to the CMO Market” at Interphex 2012
February 22, 2012
The Massachusetts Life Sciences Center (MLSC) named Pharmalucence as one of 28 Massachusetts Life Sciences companies to receive a tax incentive in return for creating new jobs in the industry.
The Massachusetts Life Sciences Center announced today that has awarded $21.2 million in tax incentives to 28 life sciences companies.
January 23, 2012
Pharmalucence begins operations at our new Corporate HeadQuarters in Billerica Massachusetts.
While manufacturing operations and personnel remain in Bedford MA while our new facility project continues, all administrative staff has now relocated to 29 Dunham Road, Billerica, MA 01821. Our toll free number remains 1-800-221-7554, but some employee direct dial numbers have changed.
December 27, 2011
Pharmalucence Supplemental New Drug Application (sNDA) for the use of Sulfur Colloid Injection (SCI) in the localization of lymph nodes in melanoma patients has been accepted for review by FDA.
July 29, 2011
Pharmalucence partners with Robert Bosch Packaging Technology for new Drug Production Facility.
July 25, 2011
Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI).
July 07, 2011
Pharmalucence partners with Integrated Project Services for design and construction of new facility.
Page 2 of 3
March 02, 2011
Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.
June 03, 2010
Pharmalucence Announces Purchase of New Property in Billerica MA. To be Developed into New Corporate Headquarters and State-of-the-Art Drug Manufacturing Facility, beginning Summer 2010.
July 10, 2009
Pharmalucence Announces Approval of Generic version of Cardiolite® Kit for the Preparation of Technetium Tc-99m Sestamibi Injection.
August 11, 2008
Pharmalucence Announces Divestiture of AeroTech® Products to Biodex Medical Systems.
January 30, 2008
Pharmalucence Announces Approval of Generic version of Choletec® Kit for the Preparation of Technetium Tc-99m Mebrofenin.
Page 3 of 3
For more information, please contact:
Director; Sales, Marketing and Customer Service
29 Dunham Road, Billerica, MA 01821 | Telephone: 781-275-7120 © Pharmalucence Inc. All rights reserved.